RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint
Filed with ASX · · 3 pages · English
Summary by 6ix AI
The analysis indicates that the imaging agent demonstrated notable tumor uptake and metabolic activity in brain metastases, confirming its potential in neuro-oncology. The company plans to host a webinar to discuss these findings further.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Half Year Report and Appendix 4D 31 December 2025
- Doses First Patient in Phase 1/2a ClinicalStudy of BetaBart (RV-01)
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
Later from Radiopharm Theranostics
- Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- RAD Doses First Patient in RAD 402 Phase 1 Clinical Study
- Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer
- Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.
- RAD202 Phase 1 HEAT Trial Advances to Dose Level 3
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics